Autologous Bone Marrow-derived Mononuclear Cells

BIOLOGICAL3 trials

Sponsors

Timothy J Nelson, MD, PhD, Timothy J. Nelson, Shanghai Changzheng Hospital

Conditions

Congenital Heart DiseaseEbstein AnomalySpinal Cord Injury

Phase 1

Phase I Safety and Feasibility Study of Intracoronary Delivery of Autologous Bone Marrow Derived Mononuclear Cells

CompletedNCT02549625

Timothy J Nelson, MD, PhDCongenital Heart Disease

Start: 2015-08-31End: 2020-11-30Updated: 2021-05-14

Study of Autologous Bone Marrow Derived Mononuclear Cells for Treatment of Ebstein Anomaly

CompletedNCT02914171

Timothy J. NelsonEbstein Anomaly

Start: 2016-09-30End: 2021-03-18Updated: 2022-04-26

Phase 2

Autologous Bone Marrow-derived Mononuclear Cells for Acute Spinal Cord Injury

Shanghai Changzheng HospitalSpinal Cord Injury

Start: 2020-10-01End: 2023-12-01Target: 45Updated: 2021-07-07

Related Papers

Statistical modeling of extracellular vesicle cargo to predict clinical trial outcomes for hypoplastic left heart syndrome.

2023-09-212 citations

Efficacy and safety of Lenzumestrocel (Neuronata-R® inj.) in patients with amyotrophic lateral sclerosis (ALSUMMIT study): study protocol for a multicentre, randomized, double-blind, parallel-group, sham procedure-controlled, phase III trial

Trials2022-05-1815 citations

Cone Reconstruction for Ebstein Anomaly: Ventricular Remodeling and Preliminary Impact of Stem Cell Therapy.

2021-09-015 citations